Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) continues to spread worldwide, with 25 million confirmed cases and 800 thousand deaths. Effective treatments to target SARS-CoV-2 are urgently needed. In the present study, we have identified a class of cyclic sulfonamide derivatives as novel SARS-CoV-2 inhibitors. Compound 13c of the synthesized compounds exhibited robust inhibitory activity (IC₅₀ = 0.88 μM) against SARS-CoV-2 without cytotoxicity (CC₅₀ > 25 μM), with a selectivity index (SI) of 30.7. In addition, compound 13c exhibited high oral bioavailability (77%) and metabolic stability with good safety profiles in hERG and cytotoxicity studies. The present study identified that cyclic sulfonamide derivatives are a promising new template for the development of anti-SARS-CoV-2 agents.

严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 继续在全球传播，已确诊 2500 万例病例和 80 万人死亡。迫切需要针对 SARS-CoV-2 的有效治疗方法。在本研究中，我们确定了一类环状磺酰胺衍生物作为新型 SARS-CoV-2 抑制剂。合成化合物中的化合物13c对 SARS-CoV-2表现出强大的抑制活性 (IC _{50 = 0.88 μM)，没有细胞毒性 (CC 50} > 25 μM)，选择性指数 (SI) 为 30.7。此外，化合物13c在 hERG 和细胞毒性研究中表现出高口服生物利用度 (77%) 和代谢稳定性以及良好的安全性。本研究确定环状磺酰胺衍生物是开发抗 SARS-CoV-2 药物的有希望的新模板。